Liang Cao

10.0k total citations · 2 hit papers
241 papers, 8.0k citations indexed

About

Liang Cao is a scholar working on Molecular Biology, Oncology and Complementary and alternative medicine. According to data from OpenAlex, Liang Cao has authored 241 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Molecular Biology, 45 papers in Oncology and 29 papers in Complementary and alternative medicine. Recurrent topics in Liang Cao's work include Ginkgo biloba and Cashew Applications (16 papers), Natural product bioactivities and synthesis (15 papers) and Neurological Disease Mechanisms and Treatments (15 papers). Liang Cao is often cited by papers focused on Ginkgo biloba and Cashew Applications (16 papers), Natural product bioactivities and synthesis (15 papers) and Neurological Disease Mechanisms and Treatments (15 papers). Liang Cao collaborates with scholars based in China, United States and Hong Kong. Liang Cao's co-authors include Nancy Kleckner, Eric Alani, Nancy Kleckner, Ruth Padmore, Wei Xiao, Zhigang Kang, Zhenzhong Wang, Yunkai Yu, Gang Ding and Kwok‐Yung Yuen and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Liang Cao

230 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pathway for generation and processing of double-strand breaks during meiotic recombination in S. cerevisiae

1990 593 citations Liang Cao et al. profile →
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Liang Cao

Since Specialization

Citations

This map shows the geographic impact of Liang Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang Cao more than expected).

Fields of papers citing papers by Liang Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liang Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang Cao. The network helps show where Liang Cao may publish in the future.

Co-authorship network of co-authors of Liang Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Liang Cao. A scholar is included among the top collaborators of Liang Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang Cao. Liang Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mindfulness interventions in post-cervical cancer: Sexual, psychological, and quality of life impact 2025 ·Psycho-Oncologie ·Junjie Qin, Yonghong Liu, Yahui Wang, Lu Li, Xiaojun Hu, Liang Cao, Lijuan Zhou, (unknown)	0
2	Dual-domain engineered exosome-based self-powered microneedle delivery platform for the treatment of infected wounds 2025 ·Materials Today Bio ·Shanguo Zhang, Tianyi Jiang, Depeng Yang, Liang Cao, Miao Li, Ju Tang, (unknown), An Xu, Li Yu, Hongyuan Jiang	0
3	Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers 2024 ·Frontiers in Oncology ·(unknown), Cody J. Peer, Xianyu Zhang, Hyoyoung Choo‐Wosoba, (unknown), Min-Jung Lee, Shraddha Rastogi, N Sato, Yunkai Yu, (unknown), Seth M. Steinberg, (unknown), Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine	3
4	Total alditols from Cistanche deserticola attenuate functional constipation by regulating bile acid metabolism 2023 ·Journal of Ethnopharmacology ·Hongmei Yin, Xia Gao, Hao Yang, (unknown), Xuening Wang, Xuesong Wang, (unknown), (unknown), Xialin Chen, Liang Cao, Chenfeng Zhang, Zhenzhong Wang, (unknown), Wei Xiao	9
5	Molecular Characterization and Clinical Characteristics of m5C-Based RNA Methylation in Spinal Cord Injury: Validated by qPCR 2022 ·International Journal of Genomics ·Liang Cao, (unknown), Qiang Zhang, Qing Li	2
6	Role of miR‐155‐5p expression and its involvement in apoptosis‐related factors in thyroid follicular carcinoma 2020 ·Journal of Clinical Pharmacy and Therapeutics ·(unknown), Yangyang Sun, (unknown), Liang Cao, Yuan Li	6
7	The therapeutic potential of ginkgolide K in experimental autoimmune encephalomyelitis via peripheral immunomodulation 2019 ·International Immunopharmacology ·Wenbo Yu, Qing Wang, Sheng Chen, Liang Cao, Jie Tang, Cungen Ma, Wei Xiao, Bao‐Guo Xiao	16
8	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors breakdown → 2018 ·Clinical Cancer Research ·Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Lisa M. Cordes, Olaf Christensen, Lisa Mahnke, Christoph Helwig, James L. Gulley	327
9	Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer 2017 ·Cancer Research ·Mingxiang Ye, Yong Zhang, Xinxin Zhang, Jianbin Zhang, Pengyu Jing, Liang Cao, Nan Li, Xia Li, Libo Yao, Jiän Zhang	42
10	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma 2017 ·Clinical Cancer Research ·Austin G. Duffy, Chi Ma, Susanna V. Ulahannan, Osama E. Rahma, Oxana V. Makarova‐Rusher, Liang Cao, Yunkai Yu, David E. Kleiner, Jane B. Trepel, Min-Jung Lee, Yusuke Tomita, Seth M. Steinberg, Theo Heller, Barış Türkbey, Peter L. Choyke, Cody J. Peer, William D. Figg, Bradford J. Wood, Tim F. Greten	68
11	Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring 2017 ·Clinical Cancer Research ·Zhigang Kang, Sanja Stevanović, Christian S. Hinrichs, Liang Cao	71
12	Investigate Mechanism of Jinzhen Oral Liquid for Respiratory Tract Infection by Using Network Pharmacology Method 2016 ·(unknown), Xinzhuang Zhang, Li Na, Liang Cao, Gang Ding, Zhenzhong Wang, Wei Xiao	0
13	SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma 2015 ·Clinical Cancer Research ·(unknown), Sven Bilke, Liang Cao, Junko Murai, Fabrício G. Sousa, Mihoko Yamade, Vinodh N. Rajapakse, Sudhir Varma, Lee J. Helman, Javed Khan, Paul S. Meltzer, Yves Pommier	70
14	Network pharmacology study on the mechanism of traditional Chinese medicine for upper respiratory tract infection 2014 ·Molecular BioSystems ·Xinzhuang Zhang, Jiangyong Gu, Liang Cao, Na Li, Yiming Ma, (unknown), Gang Ding, Lirong Chen, Xiaojie Xu, Wei Xiao	48
15	Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib 2011 ·Clinical Cancer Research ·Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel López-Chávez, (unknown), Liang Cao, Yunkai Yu, Peter L. Choyke, Barış Türkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, James R. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone	58
16	Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response 2011 ·Clinical Cancer Research ·Zhigang Kang, Junjie Chen, Yunkai Yu, Bo Li, Shi‐Yong Sun, Baolin Zhang, Liang Cao	39
17	Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer 2010 ·Cancer Research ·Liang Cao, Yunkai Yu, Sven Bilke, Robert L. Walker, Linnia H. Mayeenuddin, David O. Azorsa, Fan Yang, Marbin Pineda, Lee J. Helman, Paul S. Meltzer	174
18	Optimizing RAPD reaction system and authentic genuineness related genetic background of Fructus Evodia. 2010 ·Zhongcaoyao ·Liang Cao, Shunxiang Li, (unknown), (unknown), Fei Xu, (unknown)	5
19	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer 2008 ·Clinical Cancer Research ·William L. Dahut, Charity D. Scripture, Edwin M. Posadas, Lokesh Jain, James L. Gulley, Philip M. Arlen, James R. Wright, Yunkai Yu, Liang Cao, Seth M. Steinberg, Jeanny B. Aragon‐Ching, Jürgen Venitz, Elizabeth C. Jones, Clara C. Chen, William D. Figg	142
20	Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody 2008 ·Cancer Research ·Liang Cao, Yunkai Yu, (unknown), Duane Currier, Linnia H. Mayeenuddin, Xiaolin Wan, Chand Khanna, Lee J. Helman	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact